Newport Beach, CA, United States of America

Neil Barth

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Location History:

  • Newport Beach, CA (US) (2010 - 2017)
  • Laguna Beach, CA (US) (2020)

Company Filing History:


Years Active: 2010-2020

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Neil Barth: Innovator in Ocular Therapeutics

Introduction

Neil Barth is a prominent inventor based in Newport Beach, CA (US). He has made significant contributions to the field of ocular therapeutics, holding a total of 4 patents. His work focuses on the prevention and treatment of ocular side effects associated with various therapeutic agents.

Latest Patents

Among his latest patents, Barth has developed methods for the prevention and treatment of ocular side effects using cyclosporin. One of his notable patents discloses therapeutic methods that involve administering cyclosporin to the eye of a mammal in combination with a therapeutically active agent effective for treating cancer. This innovative approach aims to address ocular conditions that arise from the use of such agents. Another patent outlines methods for treating or preventing ocular conditions caused by certain therapeutically active agents, including chemotherapy and antiviral agents. These methods involve administering cyclosporine or its analogs to affected mammals.

Career Highlights

Throughout his career, Neil Barth has worked with notable companies, including Allergan, Inc. His expertise in ocular therapeutics has positioned him as a key figure in the development of innovative treatment methods.

Collaborations

Barth has collaborated with esteemed colleagues, including Gregg Feinerman and Rhett M Schiffman, contributing to advancements in ocular health.

Conclusion

Neil Barth's innovative work in ocular therapeutics has led to significant advancements in the treatment of ocular side effects associated with various therapeutic agents. His contributions continue to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…